Progenics HIV Drug Fast Tracked in US
Posted on: Thursday, 23 February 2006, 15:00 CST
The FDA has designated Progenics Pharmaceuticals' PRO 140 a fast track product for the treatment of HIV infection.
The fast track development program facilitates development and expedites regulatory review of drugs intended to address an unmet medical need for serious or life-threatening conditions.
PRO 140 belongs to a new class of HIV/AIDS therapeutics - viral-entry inhibitors - that are intended to protect healthy cells from viral infection. PRO 140, currently in phase Ib clinical trials in HIV-infected individuals, is a humanized monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter cells.
"Fast track status has the potential to accelerate the development of PRO 140," said Dr Paul Maddon, Progenics' chief science officer. "Although great strides have been made in HIV treatment, there is an urgent need for the development of new therapies such as PRO 140 to address the limitations of currently available HIV drugs."
With fast track designation for PRO 140, Progenics can take advantage of several programs at the FDA to streamline the regulatory review process and to work more closely with the agency on product development plans.
Source: Datamonitor
Related Articles
- Progenics Reports Positive Interim Phase 2 Results for Two Dosage Forms of Novel HIV Therapy PRO 140
- Progenics Initiates Phase 2 Clinical Trials for PRO 140, a Novel HIV Antibody Therapy
- FDA Fast-Tracks Progen's Anticancer Drug
- Progenics Presents Additional Positive Clinical Results for HIV-Entry Inhibitor PRO 140 at International AIDS Meeting
- Progenics' HIV Drug Put on Fast Track
- Progenics Pharmaceuticals' HIV Drug, PRO 140, Receives FDA Fast-Track Designation
- Schering Hepatitis Drug Gets Fast Track Status
- Starpharma's HIV Drug Fast Tracked By FDA
- Progenics Completes Enrollment in Phase 1 Clinical Trial of PRO 140, a Novel HIV Entry Inhibitor Targeting CCR5 - Potent Synergy Reported Between PRO 140 and Small-Molecule CCR5 Antagonists -
 |
 |
User Comments (0)
RSS Feeds